LL-37: The Antimicrobial Peptide Protocol

Category: Protocols Type: Protocol Read Time: 16 minutes Author: Peptides.NYC Editorial Last Updated: 2026-05-19 URL: https://peptides.nyc/learn/ll-37-protocol

Educational content only. Not medical advice. Consult a licensed healthcare provider before starting any protocol, especially if you have an autoimmune condition or active infection.

Overview

LL-37 is the only human member of the cathelicidin family of antimicrobial peptides (sometimes referred to as CAMP — cathelicidin antimicrobial peptide). It is a 37-amino-acid peptide cleaved from a larger precursor protein called hCAP18, which is stored in neutrophils, epithelial cells, and various mucosal surfaces.

Researchers including De Yang, Gallo, and Zanetti have characterized LL-37 as a dual-function molecule: it is both a broad-spectrum antimicrobial (active against bacteria, fungi, viruses, and even some parasites) and a potent immunomodulator that influences chemotaxis, wound healing, and innate immune signaling.

Key Properties

• 37 amino acids; cationic, amphipathic alpha-helical structure
• Cleaved from hCAP18 by proteinase 3 and kallikreins
• Active against Gram-positive and Gram-negative bacteria, biofilms, and enveloped viruses
• Endogenous production is strongly vitamin D dependent
• Investigated for chronic infection, biofilm disruption, wound healing, and skin disorders

LL-37 is not FDA-approved for treatment of any condition. It is sold as a research chemical and is sometimes accessed through compounding pharmacies within integrative medical practices. Regulatory status varies by jurisdiction.

Mechanism of Action

LL-37 works through several distinct but overlapping pathways:

1. Membrane disruption — Its cationic, amphipathic structure binds negatively charged microbial membranes (LPS, teichoic acid, fungal cell walls) and forms pores, causing lysis of bacteria, fungi, and enveloped viruses.
2. Biofilm penetration — Unlike many small-molecule antibiotics, LL-37 has been shown in vitro to interfere with biofilm formation and to penetrate established biofilm matrices.
3. LPS neutralization — Directly binds endotoxin, attenuating downstream TLR4-mediated inflammation.
4. Immune cell chemotaxis — Recruits neutrophils, monocytes, and T cells via FPR2 (formyl peptide receptor 2) signaling.
5. Wound healing and angiogenesis — Promotes keratinocyte migration, re-epithelialization, and new vessel formation.
6. Vitamin D feedback loop — Active 1,25-dihydroxyvitamin D upregulates the CAMP gene, driving endogenous LL-37 expression in macrophages and epithelial tissue.

This combination — direct antimicrobial activity plus immune coordination — is what makes cathelicidin biology distinct from conventional antibiotics.

Conditions Researched

LL-37 has been investigated (preclinically and in limited clinical contexts) for:

• Chronic bacterial infections — including persistent or biofilm-associated Borrelia (Lyme) and reported Bartonella co-infection scenarios
• Biofilm-related infections — chronic sinusitis, chronic wounds, dental biofilms, catheter-associated infections
• Atopic dermatitis / eczema — patients with severe eczema often show deficient cathelicidin expression in skin, which may explain their susceptibility to S. aureus colonization
• Wound healing — diabetic ulcers, slow-healing surgical wounds
• Antiviral activity — early-stage research on enveloped viruses (influenza, RSV, and ongoing interest in SARS-CoV-2)
• Mycobacterial disease — exploratory work in TB models tied to the vitamin D / cathelicidin axis

It is important to note that most human use in integrative practice is off-label, experimental, and adjunctive, not curative.

Dosing Protocols

Dosing in the research and integrative-practitioner literature is highly variable. The table below reflects ranges commonly reported in compounding-pharmacy and clinician protocols — not a prescriptive guide.

General Notes

• Start low. Because of the risk of die-off (Herxheimer-type) reactions, conservative starting doses (50–100 mcg) are often used in patients with active infection.
• Titrate slowly. Increase weekly only if tolerated.
• Reconstitute carefully. LL-37 is sensitive to heat and freeze-thaw cycles. Follow vendor or pharmacy storage instructions.
• Site rotation. Standard subcutaneous practice — rotate sites to minimize local reactions.

Lyme Disease Co-Treatment

LL-37 has attracted attention in integrative Lyme practice because:

• Borrelia burgdorferi is known to form persister cells and biofilm-like aggregates, which conventional antibiotics often fail to clear.
• In vitro work suggests cathelicidins can disrupt these structures and may synergize with antibiotics rather than replace them.
• Co-infections such as Bartonella are similarly difficult to eradicate, and some practitioners include LL-37 as part of multi-modal protocols.

Important Caveats

• LL-37 is not a primary therapy for Lyme disease. It is used adjunctively, alongside antimicrobials, herbal protocols, and clinician oversight.
• It does not cure Lyme disease, and no peer-reviewed clinical trial demonstrates eradication of Borrelia in humans with LL-37 monotherapy.
• Herxheimer-type reactions (fatigue, chills, headache, joint pain, brain fog, flu-like symptoms) are commonly reported when starting LL-37 in patients with significant microbial burden. This is one reason starting doses are kept low.

Anyone considering LL-37 for chronic infection should be working with a clinician experienced in tick-borne illness and integrative immunology.

Vitamin D Connection

One of the most well-established features of LL-37 biology is its dependence on vitamin D.

• Active 1,25-(OH)₂D binds the vitamin D receptor and upregulates the CAMP gene, increasing endogenous LL-37 production in macrophages, keratinocytes, and respiratory epithelium.
• Low 25-OH vitamin D levels are associated with reduced cathelicidin expression and may partly explain increased susceptibility to respiratory and skin infections.
• Before considering supplemental LL-37, most clinicians recommend:
  • Testing 25-hydroxyvitamin D and targeting an optimal range (commonly cited 40–60 ng/mL, individualized).
  • Adequate magnesium, which is a cofactor in vitamin D metabolism.
  • Sufficient vitamin K2, particularly with higher-dose D supplementation.

Exogenous LL-37 should be thought of as supplementing the endogenous pathway, not replacing the upstream nutritional inputs.

Side Effects & Safety

LL-37 has a relatively narrow human safety database. Reported and theoretical considerations include:

• Injection site reactions — redness, warmth, transient itching
• Herxheimer-like die-off symptoms — fatigue, fevers, chills, headache, joint aches, brain fog (especially in active chronic infection)
• Flu-like reactions in the first 1–2 weeks
• Pro-inflammatory effects at high doses — in vitro and animal data suggest that at supraphysiologic concentrations, LL-37 can shift from immunomodulatory to pro-inflammatory
• Theoretical autoimmune flare risk — see next section
• Unknown long-term safety — there is no large, long-duration human safety data

Contraindications and Cautions

• Active autoimmune disease (see below)
• Pregnancy and breastfeeding (not studied)
• Children (not studied)
• Severe immune dysregulation without clinician oversight
• Known hypersensitivity to peptide therapies

Autoimmune Caution

This is the single most important safety consideration with LL-37.

LL-37 is elevated in the lesional skin and tissue of several autoimmune conditions, and is implicated in their pathophysiology:

• Psoriasis — LL-37 binds self-DNA and self-RNA, activating plasmacytoid dendritic cells via TLR7/TLR9 and driving the IFN-alpha-mediated cascade central to psoriatic plaques.
• Rosacea — Abnormal processing of cathelicidin in rosacea skin generates pro-inflammatory peptide fragments.
• Systemic lupus erythematosus (SLE) — LL-37–self-nucleic acid complexes have been implicated as autoantigens driving type I interferon signaling.

Practical Guidance

• Avoid or use extreme caution with LL-37 in patients with psoriasis, rosacea, SLE, or other interferon-driven autoimmune conditions.
• Anyone with a strong family history or prior autoimmune flares should discuss risk-benefit thoroughly with a clinician.
• Watch carefully for new skin lesions, joint inflammation, or unexplained systemic symptoms during a course of LL-37.

The same molecule that fights infection can, in the wrong host, contribute to autoimmunity. This is not theoretical — it is well documented in dermatology and immunology literature.

Stacking

LL-37 is rarely used in isolation in integrative practice. Common pairings include:

LL-37 + Thymosin Alpha-1

• Broader immune support; thymic-modulated T-cell function
• Often used in chronic viral or post-infection convalescence
• Helps balance LL-37's narrower antimicrobial focus with whole-system immune tone

LL-37 + BPC-157

• BPC-157 supports gut barrier integrity and tissue repair
• May offset GI symptoms associated with antibiotic co-therapy or die-off
• Commonly used in chronic Lyme-type stacks where gut function is compromised

LL-37 + KPV

• KPV provides downstream anti-inflammatory balance via melanocortin signaling
• May soften inflammatory load during aggressive antimicrobial phases
• Useful when systemic inflammation is a prominent feature

Stacking decisions should be individualized — more is not always better, particularly when the goal is immune modulation rather than immune amplification.

Cycling

• Typical course: 4–8 weeks
• Extended use: Case-by-case, under clinician supervision, with periodic reassessment
• Rest periods: 2–4 weeks off between courses is common, partly to assess whether endogenous production (via vitamin D optimization) is sufficient
• Reassessment: Symptom tracking, inflammatory markers (hs-CRP, ESR), and infection-specific labs guide whether to continue, cycle, or stop

Continuous, indefinite use of LL-37 is generally not recommended given the unknowns around long-term immunomodulation and theoretical autoimmune risk.

Frequently Asked Questions

Q: Is LL-37 a replacement for antibiotics? A: No. LL-37 is investigated as a complementary or adjunctive antimicrobial, not as a substitute for evidence-based antibiotic therapy. Many practitioners pair it with conventional antimicrobials rather than replace them.

Q: Does LL-37 cure Lyme disease? A: There is no clinical evidence that LL-37 cures Lyme disease. It is used adjunctively in some integrative protocols based on in vitro biofilm and persister-cell activity. Lyme treatment should always be supervised by a qualified clinician.

Q: Will LL-37 cause a Herxheimer reaction? A: It can. Patients with significant microbial burden frequently report die-off-type symptoms — fatigue, chills, headache, joint pain — particularly in the first 1–2 weeks. Starting at lower doses and titrating slowly reduces severity.

Q: Is LL-37 safe if I have an autoimmune condition? A: Use caution or avoid. LL-37 is implicated in psoriasis, rosacea, and lupus pathophysiology. Anyone with autoimmune disease should discuss this thoroughly with their clinician before considering LL-37.

Q: Topical vs. injectable — which is better? A: Subcutaneous injection is the most commonly reported route for systemic antimicrobial protocols. Topical formulations exist in research contexts (wounds, dermatologic uses) but stability, penetration, and standardized dosing are not well established outside the lab.

Q: What about LL-37 and COVID-19? A: There is preclinical interest in cathelicidins and enveloped viruses, including SARS-CoV-2, and observational links between vitamin D status (which drives endogenous LL-37) and respiratory outcomes. This remains an area of active research, not established therapy.

Q: How do I know if I need it? A: You generally don't, unless you're working with a clinician who has evaluated specific clinical context — chronic infection workup, biofilm-related disease, or treatment-resistant conditions. Optimizing vitamin D, sleep, and baseline immune health is the appropriate first step.

Q: Is LL-37 legal? A: LL-37 is not FDA-approved for human use. It is available as a research chemical and through some compounding pharmacies under physician prescription. Legal status varies by jurisdiction — check local regulations.

Related Content

• Thymosin Alpha-1 Protocol
• BPC-157 Complete Guide
• KPV Anti-Inflammatory Protocol
• Vitamin D and Peptide Synergy
• Reconstitution Cheat Sheet
• Injection Safety Checklist

Disclaimer: This content is for educational purposes only and is not medical advice. LL-37 is a research compound and is not FDA-approved for the treatment of any disease, including Lyme disease, chronic infection, or autoimmune conditions. Information presented here is a synthesis of preclinical research and integrative clinical practice and should not be interpreted as a treatment recommendation. Consult a licensed healthcare provider before starting any peptide protocol, particularly if you have a history of autoimmune disease or active infection.

Source: https://peptides.nyc/learn/ll-37-protocol